Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001) - Concepedia

Concepedia

Publication | Closed Access

Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001)

63

Citations

26

References

2018

Year

Panagiotis A. Konstantinopoulos, William E. Brady, John Farley, Amy E. Armstrong, Denise Uyar, David M. Gershenson

Gynecologic Oncology

Gastrointestinal OncologyMedicineMetronomic TherapyGynecologyPhase Ii StudyCancer TreatmentRecurrent Clear CellOncologyRadiation OncologyFallopian Tube CancerOvarian Cancer

References

	Year	Citations

Page 1